Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action versus placebo for reflux suppression measured with the BRAVO system
2010-021630-63Phase 4Terminated
- Sponsor
- Reckitt
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing Gaviscon Double Action with Matched placebo (2 arms). Primary endpoint: Number of acid reflux events. Started Jan 2011; status: terminated.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2010-021630-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021630-63.